HilleVax (NASDAQ:HLVX) Trading Up 6.3%

Shares of HilleVax, Inc. (NASDAQ:HLVX) shot up 6.3% during trading on Monday . The stock traded as high as $13.10 and last traded at $13.08. 16,897 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 136,215 shares. The stock had previously closed at $12.30.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $28.00 price objective on shares of HilleVax in a research report on Thursday, March 21st.

HilleVax Trading Down 1.3 %

The company has a quick ratio of 10.62, a current ratio of 10.62 and a debt-to-equity ratio of 0.10. The stock’s fifty day simple moving average is $15.95 and its two-hundred day simple moving average is $14.63.

HilleVax (NASDAQ:HLVX) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.02. Sell-side analysts forecast that HilleVax, Inc. will post -3.22 earnings per share for the current fiscal year.

Insider Activity at HilleVax

In other HilleVax news, Director Aditya Kohli sold 8,866 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $14.93, for a total value of $132,369.38. Following the completion of the sale, the director now owns 812,878 shares of the company’s stock, valued at $12,136,268.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other HilleVax news, CFO Shane Maltbie sold 3,576 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $14.93, for a total transaction of $53,389.68. Following the completion of the transaction, the chief financial officer now directly owns 40,656 shares of the company’s stock, valued at approximately $606,994.08. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Aditya Kohli sold 8,866 shares of HilleVax stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $14.93, for a total value of $132,369.38. Following the completion of the transaction, the director now owns 812,878 shares of the company’s stock, valued at $12,136,268.54. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 78,039 shares of company stock worth $986,464,242. 29.30% of the stock is currently owned by company insiders.

Institutional Trading of HilleVax

A number of institutional investors and hedge funds have recently modified their holdings of HLVX. Federated Hermes Inc. raised its stake in HilleVax by 80.6% during the 3rd quarter. Federated Hermes Inc. now owns 2,113 shares of the company’s stock valued at $28,000 after acquiring an additional 943 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of HilleVax in the 4th quarter worth approximately $139,000. Seven Grand Managers LLC bought a new position in shares of HilleVax in the third quarter valued at approximately $200,000. abrdn plc bought a new stake in HilleVax during the fourth quarter worth approximately $433,000. Finally, Swiss National Bank boosted its stake in HilleVax by 47.2% during the 3rd quarter. Swiss National Bank now owns 31,200 shares of the company’s stock valued at $420,000 after purchasing an additional 10,000 shares in the last quarter. 86.42% of the stock is owned by institutional investors and hedge funds.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.